Edgewise Therapeutics reports Q4 EPS (47c), consensus (43c)

Cash, cash equivalents and marketable securities were approximately $318.4M as of December 31.” Our cash and cash equivalents at December 30, do not include the $231.8 M in net proceeds from our underwritten offering received in January 2024.”In 2023, we made tremendous progress advancing our novel muscle-targeted therapeutics in the clinic,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Most recently, we completed a successful financing enabling us to fully execute on our near and long-term goals including potential U.S. commercial launch of EDG-5506 in Becker, completion of a Phase 3 trial with EDG-5506 in Duchenne, completion of Phase 2 trials of EDG-7500 in obstructive and non-obstructive HCM and the advancement of our ongoing research and development programs.”